Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Pro Qr Therapeutics N.V. Transaction History

Mitsubishi Ufj Kokusai Asset Management Co., Ltd.

$92.2 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$0.56 - $1.0 $22,144 - $39,544	-39,544 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$0.9 - $8.39 $2,187 - $20,396	2,431 Added 6.55%	39,544 $36,000
Q4 2021 Feb 07, 2022	SELL	$6.58 - $8.44 $69,366 - $88,974	-10,542 Reduced 22.12%	37,113 $300,000
Q3 2021 Nov 04, 2021	BUY	$5.16 - $8.47 $6,635 - $10,892	1,286 Added 2.77%	47,655 $399,000
Q2 2021 Aug 06, 2021	BUY	$5.75 - $7.59 $266,621 - $351,940	46,369 New	46,369 $313,000
Q4 2019 Feb 05, 2020	SELL	$5.84 - $10.51 $70,185 - $126,309	-12,018 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$5.76 - $9.44 $8,542 - $13,999	1,483 Added 14.08%	12,018 $69,000
Q2 2019 Aug 08, 2019	BUY	$9.1 - $15.55 $18,008 - $30,773	1,979 Added 23.13%	10,535 $96,000
Q1 2019 Apr 26, 2019	BUY	$12.5 - $18.48 $19,812 - $29,290	1,585 Added 22.74%	8,556 $119,000
Q4 2018 Feb 08, 2019	BUY	$15.25 - $22.4 $106,307 - $156,150	6,971 New	6,971 $124,000

Others Institutions Holding PRQR

# of Institutions

Shares Held

17.4M

Call Options Held

37.7K

Put Options Held

21.3K

Privium Fund Management B.V.

5.63M
Shares

$20.7 Million
2.56% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

3.63M
Shares

$13.3 Million
0.01% of portfolio
Eco R1 Capital, LLC San Francisco, CA

1.84M
Shares

$6.74 Million
0.14% of portfolio
M28 Capital Management LP Stamford, CT

1.02M
Shares

$3.74 Million
1.76% of portfolio
Dafna Capital Management LLC Los Angeles, CA

906K
Shares

$3.32 Million
0.42% of portfolio

View Full List

About ProQR Therapeutics N.V.

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $262M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

More about PRQR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.

Account